References
- Guerriero S, Piscitelli D, Ciraci L, Carluccio P, Furino C, Specchia G. Hypertensive uveitis as a feature of multiple myeloma. Ocul Immunol Inflamm. 2010;18(2):104–106. doi:https://doi.org/10.3109/09273940903402645.
- Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117(2):356–365. doi:https://doi.org/10.1016/j.ophtha.2009.06.060.
- Rosenbaum JT. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol. 1994;21:123–125.
- Chen FT, Liu YC, Yang CM, Yang SH. Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci. 2012;53(7):3682–3694. doi:https://doi.org/10.1167/iovs.12-9505.
- Hsu SM, Yang CH, Shen FH, Chen SH, Lin CJ, Shieh CC. Proteasome inhibitor bortezomib suppresses nuclear factor-kappa B activation and ameliorates eye inflammation in experimental autoimmune uveitis. Mediators Inflamm. 2015;2015:847373. doi:https://doi.org/10.1155/2015/847373.
- Hsu YR, Chang SW, Yang CH, Lee YA, Kao TY. Expression profile of cationic amino acid transporters in rats with endotoxin-induced uveitis. Mediators Inflamm. 2016;2016:6586857.
- Patel DV, Horne A, House M, Reid IR, McGhee CN. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology. 2013;120(4):773–776. doi:https://doi.org/10.1016/j.ophtha.2012.10.028.